Effect of piribedil on plasma prolactin levels in women with puerperal or pathological hyperprolactinaemia.
Effect of piribedil on plasma prolactin levels in women with puerperal or pathological hyperprolactinaemia.
复制标题
吡贝地尔对产后或病理性高催乳素血症女性血浆催乳素水平的影响。
DOI：
10.1530/acta.0.0860033
复制
发表时间：
1977
期刊：
影响因子：
--
通讯作者：
P. Fioretti
中科院分区：
文献类型：
--
作者：
E. Müller;A. Genazzani;S. Murru;P. Fioretti
在患有生理性产后高泌乳素血症的女性中，吡贝地尔（100 mg po）（一种刺激多巴胺受体部位的药物）急性给药在抑制基线血浆泌乳素（PRL）水平升高方面与2-Br-α-麦角隐亭（CB 154，5 mg po）同样有效。在2例有鞍内垂体肿瘤放射学证据的高催乳素血症女性中，与CB 154（5 mg po）相比，吡贝地尔（100 mg po）未能改变血浆PRL水平，而在另外3例无垂体肿瘤放射学证据的高催乳素血症女性中，其作用不明确，即使不能与CB 154区分。这些结果表明，吡贝地尔是一种有效的血浆PRL水平的抑制剂在人类，并表明其作用是更明显的，在产后比病理性高泌乳素血症。
In women with physiological puerperal hyperprolactinaemia, acute administration of Piribedil (100 mg po), a drug which stimulates dopamine receptor sites, was as effective as that of 2-Br-alpha-ergocryptine (CB 154, 5 mg po) in suppressing the elevated baseline plasma prolactin (PRL) levels. In two hyperprolactinaemic women with radiological evidence of an intrasellar pituitary tumour, Piribedil (100 mg po), in contrast to CB 154 (5 mg po), failed to modify plasma PRL levels, whereas in 3 other hyperprolactinaemic women with no radiological evidence of pituitary tumour, its effect was not clear-cut, even though it could not be differentiated from that of CB 154. These results indicate that Piribedil is an effective suppressor of plasma PRL levels in the human and suggest that its action is more evident in puerperal than in pathological hyperprolactinaemia.